SPARTALIZUMAB for Neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 12 adverse event reports in the FDA FAERS database where SPARTALIZUMAB was used for Neoplasm malignant.
Most Reported Side Effects for SPARTALIZUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Pyrexia | 29 | 10.1% | 1 | 28 |
| Diarrhoea | 17 | 5.9% | 2 | 15 |
| Vomiting | 17 | 5.9% | 3 | 17 |
| General physical health deterioration | 14 | 4.9% | 4 | 12 |
| Colitis | 12 | 4.2% | 1 | 8 |
| Dyspnoea | 12 | 4.2% | 1 | 10 |
| Febrile neutropenia | 12 | 4.2% | 0 | 12 |
| Pneumonitis | 12 | 4.2% | 1 | 12 |
| Acute kidney injury | 11 | 3.8% | 1 | 11 |
| Nausea | 10 | 3.5% | 2 | 9 |
| Pneumonia | 9 | 3.1% | 2 | 9 |
| Urinary tract infection | 9 | 3.1% | 0 | 9 |
| Neutropenia | 8 | 2.8% | 0 | 8 |
| Thrombocytopenia | 8 | 2.8% | 0 | 8 |
| Abdominal pain | 7 | 2.4% | 2 | 5 |
Other Indications for SPARTALIZUMAB
Metastatic malignant melanoma (70)
Malignant melanoma (67)
Non-small cell lung cancer (24)
Triple negative breast cancer (19)
Pancreatic carcinoma metastatic (18)
Ductal adenocarcinoma of pancreas (9)
Pancreatic carcinoma (8)
Gastric cancer (7)
Non-small cell lung cancer metastatic (7)
Hepatocellular carcinoma (6)
Other Drugs Used for Neoplasm malignant
PALBOCICLIB (1,996)
CAPECITABINE (1,493)
PEMBROLIZUMAB (1,135)
PACLITAXEL (984)
CARBOPLATIN (977)
NIVOLUMAB (947)
OXALIPLATIN (823)
PAZOPANIB (716)
CYCLOPHOSPHAMIDE (685)
FLUOROURACIL (676)